PubMed COVID-19 Clinical Care

CONCLUSION: Drive-through vaccination is an efficient model to be redeployed for future unexpected vaccine initiatives.

BACKGROUND: At the time of our writing, the COVID-19 pandemic continues to cause significant disruption to daily lives. In Kentucky, the burdens from this disease are higher, and vaccination rates for COVID-19 are lower, in comparison to the U.S. as

The South-East Asia Region (SEAR) adopted the goal of "measles and rubella elimination by 2023". The goal was revised in 2019 to 'measles and rubella elimination by 2023' The strategies adopted to reach the goal included achieving ≥95% coverage with

[This corrects the article DOI: 10.1002/ccr3.7077.].

The COVID-19 pandemic has caused huge impacts to human health and world's econ-omy. Finding out the balance between social productions and pandemic control becomes crucial. In this paper, we first extend the SIR model by introducing two new status

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leading to pneumonia and acute respiratory distress syndrome. The COVID-19 pandemic had a major impact on the

CONCLUSIONS: Telemedicine is a safe measure to provide at-home care for people with COVID-19 infections caused by both Delta and Omicron variants.

The impact of the coronavirus disease 2019 (COVID-19) pandemic on pregnancy outcomes in Japan at the national level is unclear. This study aimed to assess the impact of the pandemic on pregnancy complications and delivery outcomes in Japan using

For many viruses, cleavage activation of membrane fusion protein by host proteases is required for infection. This knowledge is based on the historical studies on Sendai virus in the 1970s. From the 1970s to the 1990s, the avian influenza virus and

AIMS: Dipeptidyl peptidase 4 (DPP4) has been proposed as a coreceptor for SARS-CoV-2 cellular entry. Considering that type 2 diabetes mellitus (T2DM) has been identified as the most important risk factor for SARS-CoV-2, and that gliptins (DPP4